Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 43543 

the study to read and sign an informed 

consent form, and then to complete a 

short health questionnaire. After 

completing the forms, researchers will 

measure the participant’s oral 

temperature and collect two 

nasopharyngeal mucus samples and five 

ml of blood. The researchers will then 

ask the participants to don elastomeric 

masks, and breathe and cough normally 

for 40 minutes into an aerosol particle 

collection system. The total time from 

initial verbal screening to completion 

will be about 95 minutes. 

The study will require 90 volunteer 

test subjects each year for 3 years, 

totaling 270 test participants. There are 

no costs to respondents other than their 

time. The total number of annual 

burden hours are 148. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hrs.) 

Potential participant ........................................ Initial verbal screening ................................... 180 1 3/60 

Qualified participant ........................................ Informed consent form ................................... 90 1 15/60

Qualified participant ........................................ Health questionnaire ...................................... 90 1 5/60 

Qualified participant ........................................ Medical testing ............................................... 90 1 72/60 

Leroy Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2017–19748 Filed 9–15–17; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting for the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). This meeting is 

open to the public, limited only by the 

space available. The meeting room 

accommodates approximately 100 

people. The public is also welcome to 

view the meeting by webcast http://

cdclabtraining.adobeconnect.com/cliac. 

DATES: The meeting will be held on 

November 1, 2017, 8:30 a.m. to 5:00 

p.m., EDT and November 2, 2017, 8:30 

a.m. to 12:00 p.m., EDT. 

ADDRESSES: CDC, 2500 Century Center 

Boulevard, Rooms 1200/1201, Atlanta, 

Georgia 30345 and http://cdclab

training.adobeconnect.com/cliac. 

FOR FURTHER INFORMATION CONTACT: 

Nancy Anderson, MMSc, MT(ASCP), 

Chief, Laboratory Practice Standards 

Branch, Division of Laboratory Systems, 

Center for Surveillance, Epidemiology 

and Laboratory Services, Office of 

Public Health Scientific Services, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE., 

Mailstop F–11, Atlanta, Georgia 30329– 

4018, telephone (404) 498–2741; 

NAnderson@cdc.gov. 

SUPPLEMENTARY INFORMATION: Purpose: 

This Committee is charged with 

providing scientific and technical 

advice and guidance to the Secretary of 

Health and Human Services (HHS); the 

Assistant Secretary for Health; the 

Director, Centers for Disease Control 

and Prevention; the Commissioner, 

Food and Drug Administration (FDA); 

and the Administrator, Centers for 

Medicare and Medicaid Services (CMS). 

The advice and guidance pertain to 

general issues related to improvement in 

clinical laboratory quality and 

laboratory medicine practice and 

specific questions related to possible 

revision of the Clinical Laboratory 

Improvement Amendment (CLIA) 

standards. Examples include providing 

guidance on studies designed to 

improve safety, effectiveness, efficiency, 

timeliness, equity, and patientcenteredness of laboratory services; 

revisions to the standards under which 

clinical laboratories are regulated; the 

impact of proposed revisions to the 

standards on medical and laboratory 

practice; and the modification of the 

standards and provision of nonregulatory guidelines to accommodate 

technological advances, such as new 

test methods, the electronic 

transmission of laboratory information, 

and mechanisms to improve the 

integration of public health and clinical 

laboratory practices. 

Matters To Be Considered: The agenda 

will include agency updates from CDC, 

Centers for Medicare and Medicaid 

Services (CMS), and The Food and Drug 

Administration (FDA). Presentations 

and discussions will focus on laboratory 

testing in the era of telemedicine; 

antibiotic resistance testing issues; 

culture independent diagnostic tests; 

and a report from the Institute of 

Medicine (IOM) CLIAC workgroup. 

Agenda items are subject to change as 

priorities dictate. 

All people attending the CLIAC 

meeting in-person are required to 

register for the meeting online at least 5 

business days in advance for U.S. 

citizens and at least 30 business days in 

advance for international registrants. 

Register at: https://wwwn.cdc.gov/ 

cliac/. Register by scrolling down and 

clicking the ‘‘Register for this Meeting’’ 

button and completing all forms 

according to the instructions given. 

Please complete all the required fields 

before submitting your registration and 

submit no later than October 25, 2017 

for U.S. registrants and September 19, 

2017 for international registrants. 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments on 

agenda items. Public comment periods 

for each agenda item are scheduled 

immediately prior to the Committee 

discussion period for that item. In 

general, each individual or group 

requesting to make oral comments will 

be limited to a total time of five minutes 

(unless otherwise indicated). To assure 

adequate time is scheduled for public 

comments, speakers should notify the 

contact person below at least one week 

prior to the meeting date. For 

individuals or groups unable to attend 

the meeting, CLIAC accepts written 

comments until the date of the meeting 

(unless otherwise stated). However, it is 

requested that comments be submitted 

at least one week prior to the meeting 

date so that the comments may be made 

available to the Committee for their 

consideration and public distribution. 


sradovich on DSKBBY8HB2PROD with NOTICES
43544 Federal Register / Vol. 82, No. 179 / Monday, September 18, 2017 / Notices 

Written comments, one hard copy with 

original signature, should be provided 

to the contact person at the mailing or 

email address below, and will be 

included in the meeting’s Summary 

Report. 

The CLIAC meeting materials will be 

made available to the Committee and 

the public in electronic format (PDF) on 

the internet instead of by printed copy. 

Check the CLIAC Web site on the day 

of the meeting for materials: https://

wwwn.cdc.gov/cliac/. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2017–19498 Filed 9–15–17; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Healthcare 

Infection Control Practices Advisory 

Committee (HICPAC) 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) is seeking 

nominations for membership on the 

HICPAC. The HICPAC consists of 14 

experts in fields including but not 

limited to, infectious diseases, infection 

prevention, healthcare epidemiology, 

nursing, clinical microbiology, surgery, 

hospitalist medicine, internal medicine, 

epidemiology, health policy, health 

services research, public health, and 

related medical fields. Nominations are 

being sought for individuals who have 

expertise and qualifications necessary to 

contribute to the accomplishments of 

the committee’s objectives. Nominees 

will be selected based on expertise in 

the fields of infectious diseases, 

infection prevention, healthcare 

epidemiology, nursing, environmental 

and clinical microbiology, surgery, 

internal medicine, epidemiology, health 

policy, health services research, and 

public health. Federal employees will 

not be considered for membership. 

Members may be invited to serve for 

four-year terms. Selection of members is 

based on candidates’ qualifications to 

contribute to the accomplishment of 

HICPAC objectives https://

www.cdc.gov/hicpac/. 

DATES: Nominations for membership on 

the HICPAC be received no later than 

November 30, 2017. Packages received 

after this time will not be considered for 

the current membership cycle. 

ADDRESSES: All nominations should be 

mailed to HICPAC, Division of 

Healthcare Quality Promotion, NCEZID, 

CDC, 1600 Clifton Road NE., Mailstop 

A–07, Atlanta, Georgia 30333, emailed 

(recommended) to hicpac@cdc.gov, or 

faxed to (404) 639–4043. 

FOR FURTHER INFORMATION CONTACT: Erin 

Stone, M.S., HICPAC, Division of 

Healthcare Quality Promotion, NCEZID, 

CDC, 1600 Clifton Road NE., Mailstop 

A–07, Atlanta, Georgia 30333; 

Telephone (404) 639–4045; hicpac@

cdc.gov. 

SUPPLEMENTARY INFORMATION: The U.S. 

Department of Health and Human 

Services policy stipulates that 

committee membership be balanced in 

terms of points of view represented, and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens, 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on federal workgroups or 

prior experience serving on a federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. Committee 

members are Special Government 

Employees, requiring the filing of 

financial disclosure reports at the 

beginning and annually during their 

terms. CDC reviews potential candidates 

for HICPAC membership each year, and 

provides a slate of nominees for 

consideration to the Secretary of HHS 

for final selection. HHS notifies selected 

candidates of their appointment near 

the start of the term in July 2018, or as 

soon as the HHS selection process is 

completed. Note that the need for 

different expertise varies from year to 

year and a candidate who is not selected 

in one year may be reconsidered in a 

subsequent year. 

Nominees must be U.S. citizens, and 

cannot be full-time employees of the 

U.S. Government. Candidates should 

submit the following items: 

D Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address) 

D At least one letter of 

recommendation from person(s) not 

employed by the U.S. Department of 

Health and Human Services. 

(Candidates may submit letter(s) from 

current HHS employees if they wish, 

but at least one letter must be submitted 

by a person not employed by an HHS 

agency (e.g., CDC, NIH, FDA, etc.). 

Nominations may be submitted by the 

candidate him- or herself, or by the 

person/organization recommending the 

candidate. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities for both CDC and 

the Agency for Toxic Substances and 

Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2017–19501 Filed 9–15–17; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–17–17ABE] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 


sradovich on DSKBBY8HB2PROD with NOTICES